mits, "A recent CDC survey from 10 states parti

mits,

"A recent CDC survey from 10 states participating in the Active Bacterial Core Surveillance demonstrated that, although use of NAAT-based assays for GBS screening has increased since the last perinatal guidelines were published in 2010, reported use overall remained low in 2016. With more than 93% of 544 laboratories responding to the survey, only 18.7% reported using GBS NAATs for screening. Thirty-nine percent of laboratories used NAAT for antepartum screening only, 22% for intrapartum only, and 17% for both, with 21% not specifying their use context 51. Almost all (97.4%) laboratories reporting GBS NAAT use were hospital or clinic-based, compared with 12.6% use in commercial or private laboratories. In addition, 82% of laboratories using NAAT for antepartum GBS screening reported using an enrichment step before the assay was performed "

As you can see mits, as of 4 yrs ago less than 20% of the responding laboratories were using NAAT (a/k/a a PCR based test) for GBS screening. So the belief that PCR diagnostics controlled the market and shut out NNLX from GBS screening is unfounded.